Financial Planning for Australian Pharmacists: 2024-25 Update

The Australian Government's 60-day dispensing policy (stage 1 from September 2023, expanding to more medicines from January 2024) allows eligible patients to receive a 2-month supply of certain chronic condition medicines for a single co-payment. This fundamentally changes pharmacy economics.

• The reform: patients on eligible Pharmaceutical Benefits Scheme (PBS) medicines for chronic conditions can now receive 60-day supplies - halving the dispensing frequency for those patients. Each dispensing event previously generated a dispensing fee; now there are half as many events
• Revenue impact: the PBS dispensing fee is approximately $7.22 per prescription. A patient dispensed monthly generated 12 dispensing fee events per year ($86.64). On 60-day dispensing, this falls to 6 events ($43.32) - a $43.32 annual reduction per patient per eligible medicine
• Pharmacy Guild estimated aggregate impact: approximately $3.5 billion in cumulative revenue reduction across Australian community pharmacy over 5 years - averaging $300,000-$500,000 per pharmacy depending on patient mix
• Offsetting factors: pharmacies receive a 60-day dispensing incentive payment to partially compensate; some pharmacies report increased front-of-shop sales as patients who previously visited monthly now consolidate larger purchases; reduced dispensing volume frees staff time for enhanced pharmacy services
• Cash flow timing: pharmacies carrying PBS prescription stock saw inventory costs double for 60-day patients at transition (dispensing 2 months supply at once) while PBS reimbursement timing adjustments lagged. Working capital management was critical in late 2023 and 2024
• Valuations affected: pharmacy valuations based on prescription volumes and dispensing fee income are being recalibrated downward as the reform's full impact becomes apparent - buyers and sellers must now model the 60-day adjusted revenue run rate, not historical dispensing fee income

---

The 60-day dispensing reform has materially changed pharmacy valuation metrics. Buyers and sellers must now adjust their analysis to reflect the new dispensing economics rather than relying on pre-reform revenue multiples.

• Pre-reform benchmark: community pharmacies typically valued at 1.5-2.5× gross revenue or 3.0-5.0× EBITDA. Scripts-per-week metrics (typically $1,000-$2,000 per weekly script in metro areas) were widely used as a cross-check
• Post-reform adjustment: the scripts-per-week metric requires adjustment for the reduction in dispensing frequency - a pharmacy dispensing 2,000 scripts/week may now effectively deliver 1,600-1,700 equivalent services when 60-day patients are adjusted
• EBITDA-based valuation: now more reliable than revenue-based metrics for post-reform pharmacies - EBITDA captures the net profitability after PBS reforms, rental costs, staff mix, and front-of-shop contribution
• Enhanced pharmacy services revenue: pharmacies building revenue from Pharmacist-only (S3) consultations, vaccination programs (COVID, influenza, travel vaccines), staged supply services for mental health patients, MedsCheck reviews, and Home Medicines Reviews are commanding premium valuations - these services are not affected by the 60-day reform
• Location factor: pharmacies adjacent to general practice medical centres (co-located GP-pharmacy) maintain higher valuations due to script capture rate and patient relationship continuity - the 60-day reform affects GP-adjacent pharmacies less severely than standalone retail pharmacies
• Earn-out structures: post-reform pharmacy acquisitions increasingly use earn-out clauses tied to 24-month EBITDA performance rather than a fixed multiple on historical revenue - this allocates reform risk between buyer and seller

---

Pharmacist income varies significantly by employment arrangement. Understanding the tax and financial planning implications of each employment type is essential.

• Employed pharmacists (community): $75,000-$110,000 base + weekend/penalty loadings under the Pharmacy Industry Award; hospital pharmacists (clinical pharmacists) $85,000-$130,000 in the public system
• Senior pharmacists (pharmacy manager, clinical lead): $110,000-$160,000; Directors of Pharmacy (large hospital) $160,000-$220,000
• Locum pharmacists: daily rates $550-$900/day depending on location (metro vs regional vs remote); weekend rates $700-$1,100/day. Locum pharmacists can earn $200,000-$300,000+ per year while working fewer than 260 days
• Proprietor pharmacists: take-home income depends entirely on pharmacy profitability - post-reform EBITDA margins of 8-15% on revenue of $1M-$5M produces owner income of $80,000-$750,000
• HECS debt: a 4-year Bachelor of Pharmacy plus intern year accumulates approximately $60,000-$80,000 in HECS. The 2-year Master of Pharmacy (MPharm) pathway at some universities may accumulate higher debt - check Commonwealth-supported vs full-fee place status
• Salary packaging for hospital pharmacists: pharmacists employed by a public hospital can access PBI salary packaging ($15,900 FBT-free living expenses + $2,650 meal/entertainment). At $120,000 income and 37% marginal rate, this adds approximately $6,864/year in after-tax income

---

Locum pharmacists who work independently - rather than through an agency as employees - are almost always subject to PSI rules. Getting the structure right can mean the difference between paying 47% and paying 25-30% on business income.

• PSI test: if 50%+ of locum income comes from your personal pharmacy skills and efforts, it is PSI. Pharmacy locum income almost universally meets this test - pharmacies engage the specific pharmacist for their professional registration and competence
• Unrelated clients test: if more than 50% of your locum income comes from two or more unrelated pharmacy groups (not pharmacies owned by the same person or company), you may pass the unrelated clients test - exempting you from PSI rules
• Example: a locum who works 40% for Chemist Warehouse, 35% for Terry White, and 25% for an independent pharmacy has all income from unrelated clients - likely passes the test. Keep records of each pharmacy group, days worked, and income per client
• Under PSI rules: all locum income is assessed in your hands at marginal rates. You CANNOT route income through a company to be taxed at 25%, nor split income to a spouse or trust
• Outside PSI rules (unrelated clients test passed): income can flow through a company - taxed at 25% company rate. This saves 22% on income above $120,000 (47% personal vs 25% company). However, extracting the money from the company later (salary or dividends) creates additional personal tax
• Allowable PSI deductions: AHPRA registration fee, Pharmacy Guild or PSA membership, PI insurance, CPD, home office if genuinely required, pharmacy software subscriptions, uniform/workwear, work-related travel (not home-to-workplace commutes)

---

Pharmacy proprietors who own their practice premises have one of the most powerful SMSF strategies available - purchasing the pharmacy freehold inside the SMSF and leasing it back to the operating pharmacy.

• Business Real Property (BRP) exemption: a pharmacy premises (including the retail space where the pharmacy operates) qualifies as business real property - allowing the SMSF to acquire it from a related party and lease it back to the pharmacy
• Tax saving on rent: rent paid by the pharmacy to the SMSF is deductible to the pharmacy at marginal business rates (up to 47%), then assessed inside the SMSF at 15% (accumulation) or 0% (pension phase) - a 32-47% effective tax saving on every dollar of rent
• Example: $120,000/year commercial rent on pharmacy premises. Pharmacy deducts $120,000 at 37% = $44,400 tax saving. SMSF pays 15% tax on $120,000 = $18,000. Net tax saving: $44,400 − $18,000 = $26,400/year vs paying rent to an unrelated landlord at market rates
• LRBA: the SMSF can borrow to acquire the premises via a Limited Recourse Borrowing Arrangement. The loan is secured only against the property - other SMSF assets are protected if the property value falls or the loan defaults
• Capital growth tax-free in pension phase: as the pharmacy property appreciates in value, the capital gain accrues inside the super fund. If realised in pension phase, CGT is 0% - a pharmacy freehold that doubles in value generates zero CGT for a pension-phase SMSF
• Independent valuation critical: the SMSF must pay market rent for the pharmacy premises (not discounted to benefit the related party operator). Get a commercial property valuation from an independent registered valuer annually to document arm's length pricing

---

Pharmacy is a profession with strong income potential over a long career. These strategies are specifically suited to the financial profile of employed, locum, and proprietor pharmacists.

• Maximise concessional contributions: salary sacrifice up to the $30,000 CC cap (2024-25) - at $120,000 income and 37% marginal rate, every dollar sacrificed saves $0.22, building tax-sheltered super simultaneously
• Carry-forward contributions for proprietors: pharmacy proprietors whose income varies year-to-year can use carry-forward unused CC cap (available where TSB was below $500,000 in prior years) - contribute large amounts in high-income years, smooth the tax over time
• Income protection for pharmacists: own-occupation IP insurance is critical - a wrist injury, dermatitis, or mental health episode can prevent dispensing. IP insurance paying 70% of income for 2+ years provides the safety net for a high-income profession
• Pharmacy-specific KPIs for proprietors: monitor EBITDA margin (target 12-18%), scripts/day, front-of-shop revenue as % of total, enhanced services revenue (vaccination, consultations), and staff wage cost as % of revenue - these metrics determine both profitability and valuation when you sell
• Succession planning: begin pharmacy succession planning 5-10 years before intended exit. Options include family transfer, staff buyout (leveraged), sale to corporate group, or a merger into a banner group (Chemist Warehouse, Terry White, Priceline). Each pathway has different CGT and personal income tax outcomes
• Diversification outside pharmacy: proprietary pharmacists whose wealth is entirely tied to their pharmacy value face concentration risk. ETF investing and investment property alongside the pharmacy business provides wealth that is not correlated with pharmacy reform risk or healthcare policy

---

Pharmacists work at the front line of Australian healthcare - managing complex medication regimens, providing community health advice, and keeping the PBS system running. Roopon helps pharmacists and healthcare professionals reduce everyday spending with exclusive discounts at hundreds of Australian retailers, dining venues, and service providers.

from $19.99/month, Roopon membership delivers consistent savings above the cost, plus FREE included prize-draw entries (per campaign terms). Join Roopon today. ABN 89 656 278 830 | 172-178 Maroubra Road, Maroubra NSW 2035.

---

Join Roopon today for partner discounts and FREE included prize-draw entries per your plan and published campaign terms.

Join ROOPON Now